US2014335114A1PendingUtilityA1
Hyr1 as a target for active and passive immunization against candida
Assignee: LOS ANGELES BIOMED RES INSTPriority: Jul 3, 2009Filed: Apr 17, 2014Published: Nov 13, 2014
Est. expiryJul 3, 2029(~2.9 yrs left)· nominal 20-yr term from priority
A61K 39/0002A61P 31/10C07K 14/40A61P 37/02C07K 2319/21A61P 37/04A61K 39/00A61K 38/16
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A vaccine comprising a polypeptide substantially identical to a fragment of a HYR1 polypeptide.
2 . The vaccine of claim 1 , wherein said HYR1 polypeptide is
(SEQ ID NO.: 1)
1
MKVVSNFIFTILLTLNLSAALEVVTSRIDRGGIQGFHGD
VKVHSGATWAILGTTLCSFFG
61
GLEVEKGASLFIKSDNGPVLALNVALSTLVRPVINNGVI
SLNSKSSTSFSNFDIGGSSFT
121
NNGEIYLDSSGLVKSTAYLYAREWTNNGLIVAYQNQKAA
GNIAFGTAYQTITNNGQICLR
181
HQDFVPATKIKGTGCVTADEDTWIKLGNTILSVEPTHNF
YLKDSKSSLIVHAVSSNQTFT
241
VHGFGNGNKLGLTLPLTGNRDHFRFEYYPDTGILQLRAD
ALPQYFKIGKGYDSKLFRIVN
301
SRGLKNAVTYDGPVPNNEIPAVCLIPCTNGPSAPESESD
LNTPTTSSIETSSYSSAATES
361
SVVSESSSAVDSLTSSSLSSKSESSDVVSSTTNIESSS
TAIETTMNSESSTDAGSSSISQ
421
SESSSTAITSSSETSSSESMSASSTTASNTSIETDSGI
VSQSESSSNALSSTEQSITSSP
481
GQSTIYVNSTVTSTITSCDENKCTEDVVTIFTTVPCS
TDCVPTTGDIPMSTSYTQRTVTS
541
TITNCDEVSCSQDVVTYTTNVPHTTVDATTTTTTST
GGDNSTGGNESGSNHGPGNGSTEG
601
SGNGSGAGSNEGSQSGPNNGSGSGSEGGSNNGSGSD
SGSNNGSGSGSNNGSGSGSTEGSE
661
GGSGSNEGSQSGSGSQPGPNEGSEGGSGSNEGSNHG
SNEGSGSGSGSGSNNGSGSGSQSG
721
SGSGSQSGSESGSNSGSNEGSNPGAGNGSNEGSG
QGSGNGSEAGSGQGSGPNNGSGSGHN
781
DGSGSGSNQGSNPGAGSGSGSESGSKAGSHSGSN
EGAKTDSIEGFHTESKPGFNTGAHTD
841
ATVTGNSVANPVTTSTESDTTISVTVSITSYMTG
FDGKPKPFTTVDVIPVPHSMPSNTTD
901
SSSSVPTIDTNENGSSIVTGGKSILFGLIVSMVVLFM.
3 . The vaccine of claim 1 , further comprising an adjuvant.
4 . The vaccine of claim 1 , wherein said fragment of the HYR1 polypeptide is expressed in a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata , and Candida parapsilosis.
5 . The vaccine of claim 1 , wherein said fragment consists of an N-terminal region fragment of the HYR1 polypeptide.
6 . The vaccine of claim 4 , wherein said fragment is
(SEQ ID NO.: 2)
1
TSRIDRGGIQ GFHGDVKVHS
21
GATWAILGTT LCSFFGGLEV
41
EKGASLFIKS DNGPVLALNV
61
ALSTLVRPVI NNGVISLNSK
81
SSTSFSNFDI GGSSFTNNGE
101
IYLASSGLVK STAYLYAREW
121
TNNGLIVAYQ NQKAAGNIAF
141
GTAYQTITNN GQICLRHQDF
161
VPATKIKGTG CVTADEDTWI
181
KLGNTILSVE PTHNFYLKDS
201
KSSLIVHAVS SNQTFTVHGF
221
GNGNKLGLTL PLTGNRDHFR
241
FEYYPDTGIL QLRAAALPQY
261
FKIGKGYDSK LFRIVNSRGL
281
KNAVTYDGPV PNNEIPAVCL
301
IPCTNGPSAP ESESDLNTPT
321
TSSIET.
7 . The vaccine of claim 6 , wherein said fragment is a fusion polypeptide.
8 . The vaccine of claim 7 , wherein in said fragment is fused to a heterologous leader sequence.
9 . The vaccine of claim 7 , wherein said fragment is fused to a tag or a linker sequence.
10 . The vaccine of claim 6 , wherein said tag is a histidine tag.
11 . The vaccine of claim 1 , wherein said fragment is obtained from a transformed cell.
12 . The vaccine of claim 11 , wherein said transformed cell is a transformed Saccharomyces cerevisae cell.
13 . A method of treating or preventing a candidiasis infection, said method comprising administering an immunogenic amount of a vaccine of claim 1 .
14 . The method of claim 13 , wherein said candidiasis infection is disseminated candidiasis.
15 . The method of claim 13 , wherein said administering comprises active immunization, passive immunization, or a combination thereof.
16 . A method of treating or preventing a candidiasis infection, said method comprising administering an effective amount of an isolated polypeptide substantially identical to a fragment of a HYR1 polypeptide.
17 . The method of claim 16 , wherein said fragment of the HYR1 polypeptide is expressed in a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata , and Candida parapsilosis.
18 . The method of claim 16 , wherein said fragment consists of an N-terminal region fragment of the HYR1 polypeptide.
19 . The method of claim 18 , wherein said fragment is SEQ ID NO:2.
20 . The method of claim 19 , wherein said fragment is a fusion polypeptide.
21 . The method of claim 20 , wherein in said fragment is fused to a heterologous leader sequence.
22 . The method of claim 21 , wherein said fragment is fused to a tag or a linker sequence.
23 . The method of claim 22 , wherein said tag is a histidine tag.
24 . The method of claim 16 , wherein said fragment is obtained from a transformed cell.
25 . The method of claim 24 , wherein said transformed cell is a transformed Saccharomyces cerevisae cell.Join the waitlist — get patent alerts
Track US2014335114A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.